Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
申请人:——
公开号:US20040077605A1
公开(公告)日:2004-04-22
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
申请人:Salvati E. Mark
公开号:US20050119228A1
公开(公告)日:2005-06-02
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
申请人:Regen BioPharma, Inc.
公开号:US20180214413A1
公开(公告)日:2018-08-02
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
Fluorescentlylabeled calix[4]arene glycoconjugates demonstrate multifunctional potential in both Warburg effect mediated tumor imaging and GLUT1 targeted drug delivery. Nitrobenzoxadiazole and mannose conjugated NBD-Man-CA was found to be selectively recognized by GLUT1 and act as a “molecular carrier” for selective tumor targeting.